GlassScriptPhysician profile
Erik W Springer
NPI 1194711622
$11,228.53
in general payments reported to CMS, 2019-2025
41 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $605 · 2021: $1,629 · 2022: $1,935 · 2023: $1,828 · 2024: $1,953 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,900 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50 · Education: $52.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,899.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
| Education | $52.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,545.62 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Gilead Sciences, INC. | $970.04 | 2019-2025 | |
| Janssen Biotech, INC. | $770.65 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $725.36 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $621.82 | 2023-2025 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $590.64 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $506.71 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $427.46 | 2023-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $398.23 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $367.64 | 2019-2025 | |
| Allergan, INC. | $239.46 | 2019-2020 | |
| Qol Medical, LLC | $235.28 | 2019-2025 | Sucraid |
| Intercept Pharmaceuticals, INC. | $225.49 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $187.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Celltrion USA INC. | $140.39 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Springer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.